Anavex Life Sciences Corp (AVXL)

[falconer66a]

Parkinson's Info at an Alzheimer's Conference?

So, Anavex is going to be releasing results of their clinical study of blarcamesine to treat Parkinson's disease dementia at, of all places, a major Alzheimer's conference. Does that make any sense? Parkinson's and Alzheimer's are two, distinctly different diseases. Ostensibly, this is a gross error. The results should be presented at a Parkinson's disease conference.

Of course, it's not a mistake. Anavex is taking advantage of the CTAD conference to present the Parkinson's results before a multitude of Alzheimer's experts and researchers, all of whom will quickly understand the presented data, and more importantly, grasp their applications for the treatment (or prophylaxis) of Alzheimer's.

Once and for all, this clever maneuver will validate and confirm the blarcamesine mechanism(s) of action, facilitating favorable activation of the sigma-1 receptor protein. The Alzheimer's people are going to see the quite favorable Parkinson's results, and then have to explain to various Alzheimer's stakeholders why they haven't taken this approach to Alzheimer's. "Wow, look at what that drug did for people with Parkinson's. And Anavex is testing it on people with Alzheimer's. No doubt, blarcamesine is now in the Alzheimer's game."

After the CTAD conference, everything discussed and written about blarcamesine will be different.